Results 121 to 130 of about 14,163 (275)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy

iScience, 2023
Summary: Inhibitors of neprilysin improve glycemia in patients with heart failure and type 2 diabetes (T2D). The effect of weight loss by diet, surgery, or pharmacotherapy on neprilysin activity (NEPa) is unknown.
Sasha A.S. Kjeldsen, Lise L. Gluud, Mikkel P. Werge, Julie S. Pedersen, Flemming Bendtsen, Kleopatra Alexiadou, Tricia Tan, Signe S. Torekov, Eva W. Iepsen, Nicole J. Jensen, Michael M. Richter, Jens P. Goetze, Jørgen Rungby, Bolette Hartmann, Jens J. Holst, Birgitte Holst, Joachim Holt, Finn Gustafsson, Sten Madsbad, Maria S. Svane, Kirstine N. Bojsen-Møller, Nicolai J. Wewer Albrechtsen   +21 more
doaj  

Brush border digestion : development of a physiologically relevant in vitro model : a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Physiology at Massey University, Manawatū, New Zealand [PDF]

, 2018
Chapter Two has, in part, been published in the Springer publication, Reviews of Physiology, Biochemistry and Pharmacology, but the Author retains the right to publish the material in any collection consisting of the Author's own works: Hooton, D ...
Hooton, Diane Frances
core  

From ARB to ARNI in Cardiovascular Control [PDF]

, 2016
Coexistence of hypertension, diabetes mellitus and chronic kidney disease synergistically aggravates the risk of cardiovascular and renal morbidity and mortality.
Danser, A.H.J. (Jan), Hoorn, E.J. (Ewout), Roksnoer, L.C.W. (Lodi), Uijl, E. (Estrellita)   +3 more
core   +1 more source

Cost‐utility analysis of add‐on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China

ESC Heart Failure, EarlyView.
Abstract Aims The study aimed to analyse the cost‐utility of Chinese patent medicine Qili Qiangxin (QLQX) capsules in heart failure with a reduced ejection fraction from the healthcare payer's perspective. Methods and results From the perspective of the healthcare payer, a Markov model was established to estimate the cost‐utility of adding QLQX ...
Lu Wang, Yinglin Wang, Quan Zhao
wiley   +1 more source

Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications

Frontiers in Pharmacology
Neprilysin (NEP), a zinc-dependent membrane-bound metallopeptidase, regulates various bioactive peptides, particularly in kidneys, vascular endothelium, and the central nervous system.
Xinyue Zhang, Chun Hu, Erkang Tian, Yanxin Shen, Wei Liu, Juan Li   +5 more
doaj   +1 more source

Prescription of guideline‐directed medical therapy in heart failure: impact on mortality and readmission

ESC Heart Failure, EarlyView.
Routine data analysis showing a better outcome regarding mortality and readmission in HF patients when being prescribed the current four‐drug treatment (vs. the outdated two‐drug therapy) 91–365 days after index hospital stay. Abstract Aims The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy ...
Martin Möckel, Samipa Pudasaini, Kristina Feldmann, Henning Thomas Baberg, Benny Levenson, Jürgen Malzahn, Thomas Mansky, Guido Michels, Christian Günster, Elke Jeschke   +9 more
wiley   +1 more source

Exercise oscillatory ventilation in patients with advanced heart failure with and without left ventricular assist device

Artificial Organs, Volume 47, Issue 1, Page 168-179, January 2023., 2023
Peak oxygen consumption, VO2peak, was associated with short‐term 3‐months‐rehospitalization in heart failure patients with reduced ejection fraction (HFrEF). Exercise oscillatory ventilation (EOV), representing fluctuations of pulmonary artery pressure, can be observed in heart failure patients with reduced ejection fraction with and without left ...
Simon Wernhart, Maria Papathanasiou, Aiste Jakstaite, Julia Hoffmann, Bastian Schmack, Jürgen Hedderich, Arjang Ruhparwar, Tienush Rassaf, Peter Luedike   +8 more
wiley   +1 more source

Phosphodiesterase 9 Inhibition Combined With Valsartan and With Sacubitril/Valsartan in Experimental Ovine Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background LCZ696 (sacubitril/valsartan) antagonizes the renin–angiotensin system while simultaneously augmenting the natriuretic peptides (NPs). Inhibition of phosphodiesterase 9 inhibition (PDE9i), which hydrolyses NP‐generated cGMP may be a more ...
Nicola J. A. Scott, Christopher J. Charles, Timothy C. R. Prickett, Christopher M. Frampton, A. Mark Richards, Miriam T. Rademaker   +5 more
doaj   +1 more source

No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril

Journal of the American College of Cardiology, 2019
Cellular and molecular bases of the beneficial effects of sacubitril/valsartan, an angiotensin receptor/neprilysin inhibitor approved for treatment of heart failure with reduced ejection fraction, remain to be elucidated, because of the lack of preclinical mechanistic studies.
Vergaro G., Passino C., Emdin M.
openaire   +3 more sources

Early prescription of quadruple therapy in acute decompensated heart failure with reduced ejection fraction: A propensity score‐matched analysis

ESC Heart Failure, EarlyView.
This propensity score‐matched analysis of 2051 acute decompensated heart failure patients from the ICARUS registry compared 898 patients who received early quadruple guideline‐directed medical therapy (within 48 h of admission) to 1153 matched controls.
Luis E. Echeverría, Lyda Z. Rojas, Angie Yarlady Serrano‐García, Daniel Botero, Karen Andrea García‐Rueda, Ángela Torres‐Bustamante, Diana Ivonne Cañón‐Gómez, Juan Sebastián Salcedo, Alexandra Hurtado‐Ortiz, Jaime A. Rodríguez, Sergio A. Gómez‐Ochoa   +10 more
wiley   +1 more source